Harrow relaunches biosimilar Byooviz in the US
Harrow Inc. has re-launched BYOOVIZ (ranibizumab-nuna) in the U.S. commercial market, stemming from a partnership with Samsung Bioepis Co., Ltd. BYOOVIZ is an intravitreally-administered injection for treating wet age-related macular degeneration, macular edema following retinal vein occlusion, and myopic choroidal neovascularization. It was the first ophthalmic biosimilar approved by the FDA in 2021 and received interchangeable designation in 2023, allowing pharmacists to substitute it for the reference product, Lucentis, without a new prescription.
Price to book forward of Harrow, Inc. – NASDAQ:HROW
The article references the "Price to book forward" for Harrow, Inc. (NASDAQ: HROW) and appears to be a financial data page from TradingView. It provides basic stock information and navigation elements, but the substantive financial data itself is not displayed in this snippet. The content primarily focuses on the interface and disclaimers of TradingView and its data providers.
Price to sales forward of Harrow, Inc. – NASDAQ:HROW
This article provides the "Price to sales forward" metric for Harrow, Inc. (NASDAQ: HROW) as presented on TradingView. It indicates that the market was closed at the time of viewing, with no trades reported. The content also briefly lists various financial data sources and features available on the TradingView platform.
Enterprise value to EBITDA forward of Harrow, Inc. – NASDAQ:HROW
This article displays the "Enterprise value to EBITDA forward" for Harrow, Inc. (NASDAQ:HROW) on TradingView. It shows that the value is not available ("No trades") and provides information about the data sources used on the platform. The main focus is presenting a specific financial metric for the company.
Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow
Samsung Bioepis has relaunched BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar to LUCENTIS, in the United States through a new partnership with Harrow. This relaunch aims to enhance access to critical retinal disease treatments like those for Wet Age-Related Macular Degeneration. The collaboration sees Samsung Bioepis managing development and manufacturing, while Harrow handles commercialization across the US.
Enterprise value to revenue forward of Harrow, Inc. – NASDAQ:HROW
The article provides financial information for Harrow, Inc. (NASDAQ: HROW), specifically its enterprise value to revenue forward. It appears to be a stub or a section from a larger financial data platform, showing the company's ticker, market, and a period-specific value with change metrics.
Harrow brings an interchangeable eye-drug biosimilar to U.S. retina care
Harrow (Nasdaq: HROW) has launched BYOOVIZ (ranibizumab-nuna) in the U.S., an FDA-approved interchangeable biosimilar referencing LUCENTIS for various retinal conditions like Wet AMD. This launch, following an exclusive commercialization agreement with Samsung Bioepis, expands Harrow's retina portfolio in the estimated $9 billion U.S. anti-VEGF market. The company aims to provide retina specialists with a trusted and economically valuable treatment option, alongside its existing products IHEEZO and TRIESENCE.
Harrow Announces Commercial Launch of BYOOVIZ® in the United States
Harrow, Inc. has commercially launched BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTIS, in the U.S. This launch expands Harrow's retina portfolio for treating conditions like Neovascular Age-Related Macular Degeneration (AMD). The company obtained exclusive U.S. commercialization rights through a partnership with Samsung Bioepis, further strengthening its presence in the growing retinal biologics market.
Harrow Announces Commercial Launch of BYOOVIZ® in the United States
Harrow has commercially launched BYOOVIZ® (ranibizumab-nuna) in the United States, an FDA-approved interchangeable biosimilar to LUCENTIS, expanding its retina portfolio. This launch follows an exclusive agreement with Samsung Bioepis and aims to provide retina specialists with a clinically proven anti-VEGF therapy for conditions like Wet Age-Related Macular Degeneration. BYOOVIZ joins other Harrow products like IHEEZO and TRIESENCE, strengthening the company's position in the rapidly growing retinal biologics market.
A first FDA-approved eye biosimilar returns to U.S. sales
Samsung Bioepis has relaunched BYOOVIZ (ranibizumab-nuna) in the US in partnership with Harrow, making the FDA-approved ophthalmology biosimilar referencing LUCENTIS available again. BYOOVIZ was the first ophthalmology biosimilar approved by the FDA in 2021 and received interchangeability designation in 2023. This collaboration aims to improve patient access to critical retinal disease treatments and address the financial burden associated with current anti-VEGF therapies for conditions like Wet Age-Related Macular Degeneration.
Harrow Announces Commercial Launch of BYOOVIZ® in the United States
Harrow, Inc. has launched BYOOVIZ® (ranibizumab-nuna) in the United States, an FDA-approved interchangeable biosimilar to LUCENTIS, developed by Samsung Bioepis. This launch expands Harrow's retina portfolio for treating conditions like Age-Related Macular Degeneration (AMD) and Macular Edema. The company aims to provide more treatment options and economic value for retina specialists, reinforcing its presence in the growing $9 billion U.S. anti-VEGF market.
How Grow Funds’ Exit and Weaker Earnings Recast Harrow’s (HROW) Growth Narrative and Governance Choices
Harrow, Inc.'s recent annual meeting approved director nominees and executive compensation, but Grow Funds' exit and disappointing earnings have cast doubt on the company's growth narrative. Investors are now more closely scrutinizing Harrow's ability to execute on product launches and meet its ambitious revenue guidance for 2026, especially given its reliance on a few key products. The company projects significant revenue and earnings growth by 2029, resulting in a fair value estimate much higher than its current price.
Harrow, Inc. Actuals & Estimates (NASDAQ:HROW)
This article provides an overview of Harrow, Inc. (HROW) stock, including its current price, market capitalization, historical performance, and financial estimates. It details analyst forecasts, past earnings reports, future earnings dates, and revenue figures, emphasizing that this information is not investment advice and encourages personal research.
HROW Forecast — Price Target — Prediction for 2027
This article provides a forecast for Harrow, Inc. (HROW) stock, including its current price, historical highs and lows, and analyst predictions for 2027. It also details financial metrics such as market capitalization, recent earnings, revenue, EBITDA, and upcoming earnings report dates. The volatility and beta coefficient of the stock are also mentioned.
How Grow Funds’ Exit and Weaker Earnings Recast Harrow’s (HROW) Growth Narrative and Governance Choices
Harrow, Inc. recently held its 2026 Annual Meeting, approving director nominees and executive compensation, with Deloitte & Touche LLP ratified as auditor. However, Grow Funds exited its position due to disappointing earnings and a slight reduction in hedge fund ownership, raising concerns about Harrow's ability to meet its ambitious revenue guidance and growth targets. This puts Harrow's reaffirmed 2026 revenue guidance of US$350 million to US$365 million under scrutiny, highlighting the market's sensitivity to execution on product launches and overall performance.
GROW Small Cap Equity Fund Covered Its Position in Harrow (HROW) in Q1
The GROW Small Cap Equity Fund covered its position in Harrow, Inc. (HROW) during Q1 2026, citing a disconnect between high street earnings expectations and the company's underlying growth. While the fund acknowledged Harrow's long-term potential, its conviction shifted towards AI stocks with higher and quicker return potential. The fund returned 4.18% in Q1 2026, outperforming several key indices amidst market volatility.
Form 4 Harrow Health Inc For: 22 June By Investing.com
This article announces a Form 4 filing for Harrow Health Inc., dated June 22. It briefly mentions the company's stock symbol, HROW, and its -1.07% performance, alongside other financial market data and news headlines.
Harrow (HROW) director Adrienne Graves receives 5,248 RSUs as compensation grant
Harrow, Inc. (HROW) director Adrienne L. Graves has been granted 5,248 Restricted Stock Units (RSUs) as compensation for her services. These RSUs will vest in equal quarterly installments over one year, contingent on her continued service. The underlying shares will not be delivered or become transferable until her termination of service.
[Form 4] HARROW, INC. Insider Trading Activity
HARROW, INC. director Perry J. Sternberg reported the acquisition of 5,248 restricted stock units (RSUs) as compensation. These RSUs vest in equal quarterly installments over one year and will only be delivered as common shares after his service with the company ends. This transaction was detailed in a Form 4 filing, indicating a neutral impact and sentiment.
Form 8K Harrow Health Inc For: 22 June By Investing.com
This article reports on the filing of a Form 8K by Harrow Health Inc. for June 22nd. It provides the stock symbol HROW and mentions its current performance. The content is brief and serves primarily as an announcement of the filing.
Harrow elects directors and approves executive compensation at annual meeting By Investing.com
Harrow, Inc. (NASDAQ: HROW) shareholders elected four directors to its board, approved executive compensation, and ratified Deloitte & Touche LLP as its accounting firm during the 2026 Annual Meeting of Stockholders. The company's shares have seen significant gains over the past year, and an InvestingPro analysis suggests the stock is undervalued with strong revenue growth. Separately, Harrow recently reported Q1 2026 financial results below analyst expectations but also announced the relaunch of its VERKAZIA treatment.
Harrow elects directors and approves executive compensation at annual meeting
Harrow, Inc. (NASDAQ: HROW) held its 2026 Annual Meeting where shareholders elected four directors to the board, approved executive compensation on an advisory basis, and ratified Deloitte & Touche LLP as its independent accounting firm for 2026. The company has seen a 10% stock gain over the past week and nearly 40% over the past year, with a market capitalization of $1.6 billion. This news follows a recent report of Harrow Health Inc. missing Q1 2026 analyst expectations for EPS and revenue, but also announcing the relaunch of VERKAZIA.
Harrow (HROW) investors back all 2026 director, pay and auditor proposals
Harrow, Inc. shareholders approved all proposals at their 2026 annual meeting, including the election of four directors, advisory approval of executive officer compensation, and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the 2026 fiscal year. A significant majority of the 37,273,420 eligible shares were represented, with 29,830,973 shares present or by proxy, confirming strong investor support for the company's governance and compensation practices.
Spotlight On Harrow And 2 Other Growth Stocks With Strong Insider Backing
This article highlights Harrow (HROW), Alphatec Holdings (ATEC), and AvePoint (AVPT) as growth stocks with significant insider ownership, suggesting strong confidence from management. Harrow, an eyecare pharmaceutical company, expects substantial revenue growth and future profitability despite recent losses. Alphatec Holdings, a medical technology company, shows strong insider buying and anticipates profitability, trading below its fair value. AvePoint, a cloud data management platform, also trades below its estimated fair value and projects robust revenue growth with solid insider ownership.
Harrow Inc (HROW) Financial Health: Profitability & Balance Sheet Analysis
Harrow Inc (HROW) holds a stable financial status with a score of 7.49, ranking 117th in the Pharmaceuticals industry. While its operating efficiency is high, the company reported a year-over-year revenue decrease of 7.59% and a significant net profit decrease of 55.24% in its latest quarter. The analysis highlights key financial dimensions including quality of earnings, operational efficiency, growth potential, and shareholder returns, though some relevant data are yet to be disclosed.
Harrow Inc (HROW) Institutional Confidence
This article analyzes Harrow Inc.'s (HROW) institutional confidence, noting its current shareholding score of 5.00, placing it 73rd out of 157 in the Pharmaceuticals industry. Institutional shareholding has increased to 66.17% quarter-over-quarter. Private Capital is the largest institutional shareholder with 1.60M shares.
Harrow Inc (HROW) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Harrow Inc's (HROW) dividend and stock split history. It indicates that Harrow Inc has not distributed any dividends in the past five years and has no recorded stock split data. The current stock price and market capitalization are also listed.
Harrow Inc (HROW) Earnings Forecast: Future EPS & Revenue Growth Estimates
Harrow Inc (HROW) has an earnings forecast score of 8.75 and an average analyst price target of USD 69.00, suggesting a potential upside of 68.43%. Analysts predominantly rate the stock as a "Buy," with the company's expected revenue for the next quarter at USD 70.95 million. Despite a previous quarter EPS of USD 0.18 against an expectation of USD -0.74, the next quarter's EPS is projected to be USD -0.17.
What Harrow (HROW)'s VERKAZIA Re‑Launch in Pediatric VKC Means For Shareholders
Harrow (HROW) recently re-launched VERKAZIA for pediatric vernal keratoconjunctivitis, aiming to provide a steroid-sparing treatment option. This re-launch supports Harrow's diversification strategy, reducing its reliance on a few key products, though the company still faces challenges with high operating costs and ambitious revenue targets. Investors are watching to see if VERKAZIA can significantly contribute to Harrow's long-term revenue and earnings goals, which analysts project to reach $784.8 million revenue and $246.0 million earnings by 2029.
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US
Harrow's (HROW) stock increased by 7.3% following the relaunch of its FDA-approved ophthalmology drug Verkazia in the United States. Verkazia is designed to treat vernal keratoconjunctivitis (VKC), a chronic inflammatory eye disease primarily affecting children, offering a steroid-sparing alternative to current treatments. The relaunch aims to improve patient access and ensure a consistent supply of this critical medication, addressing previous availability challenges.
HROW Stock Rips Higher As Traders Digest Mixed Quarter
Harrow Inc. (HROW) stock surged by 9.8% after the company released a mixed Q1 earnings report, which included a wider loss and a revenue dip attributed to an $8M adjustment for its VEVYE dry eye product. Despite the initial financial hit, management reiterated full-year goals, anticipating improved VEVYE reimbursement in Q2 2026, leading to a bullish outlook from analysts and significant insider buying. Traders are viewing Q1 as a reset rather than a collapse, focusing on forward guidance and strong demand.
Analysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), GeneDx Holdings (WGS)
Analysts are maintaining a bullish stance on two healthcare stocks: Harrow Health (HROW) and GeneDx Holdings (WGS). Craig-Hallum analysts Chase Knickerbocker and William Bonello reiterated Buy ratings for HROW and WGS, respectively, with significant upsides projected from current price levels. Both companies also received supporting Buy ratings from other firms recently.
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic
Harrow has re-launched VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for the treatment of vernal keratoconjunctivitis (VKC), a serious allergic eye disease primarily affecting children. This re-launch aims to address a significant unmet need by ensuring dependable supply, removing access barriers, and offering a steroid-sparing treatment for long-term VKC management. VERKAZIA targets the underlying inflammatory mechanisms of VKC, providing an important advancement for clinicians managing this complex disease, particularly given the risks associated with chronic steroid use in pediatric patients.
Return on invested capital % of Harrow, Inc. – FWB:3IP
This article focuses on the "Return on invested capital %" for Harrow, Inc. (FWB:3IP), listed on the Frankfurt Stock Exchange within the health technology and pharmaceuticals sector. The content appears to be a financial data point from TradingView, indicating no current trading activity.
What Does Cantor Fitzgerald Think About Harrow (HROW) After Cutting Its Price Target?
Cantor Fitzgerald analyst Steve Seedhouse recently lowered his price target for Harrow, Inc. (HROW) from $91 to $88, while maintaining an "Overweight" rating. This adjustment followed Harrow's Q1 2026 earnings report, where a one-time $8 million gross-to-net revenue adjustment for its VEVYE dry eye drug impacted revenue expectations despite record prescriptions. Harrow, an ophthalmic pharmaceutical company, saw this pricing pressure as a non-recurring event, which influenced the analyst's revised revenue forecast and price target.
William Blair Maintains Harrow(HROW.US) With Buy Rating
William Blair has reiterated its Buy rating for Harrow (HROW.US). This indicates continued confidence in the company's stock performance from the analytical firm.
Harrow files Regulation FD disclosure to furnish June 2026 corporate presentation
Harrow (HROW) has filed a Regulation FD disclosure to furnish its June 2026 corporate presentation for investors and analysts. This presentation, submitted as Exhibit 99.1 on a Form 8-K, will be used by management at investor conferences and meetings. The information provided is not considered "filed" under Section 18 of the Exchange Act.
Harrow (NASDAQ: HROW) posts June 2026 corporate investor presentation
Harrow, Inc. has filed an 8-K report announcing its June 2026 corporate investor presentation. This presentation, furnished under Regulation FD, will be used by management at investor conferences and meetings with analysts and other interested parties. The company emphasized that this material is "furnished" rather than "filed," meaning it is not subject to certain liability provisions and is not automatically incorporated into other SEC filings unless explicitly referenced.
Harrow Health earnings on deck: Can branded drugs offset California exit?
Harrow Health (HROW) is expected to report a first-quarter loss of $0.35 per share on revenue of $52.55 million, a significant decline from the previous quarter, largely due to the exit of its California compounding business. Despite this, analysts remain optimistic with a "Strong Buy" rating and a target price implying 78% upside, banking on the company's branded ophthalmic portfolio and pipeline developments to drive sustainable growth. Investors are keen to see how the company's commercial expansion efforts and branded drug sales will mitigate the revenue impact from its compounding business contraction.
Top 5 Small Cap Stocks With Huge Growth Potential
This article highlights small cap stocks with significant growth potential, focusing on Harrow, Inc. (NASDAQ: HROW) as one of the top picks. Despite a downward revision in price target by an analyst due to near-term revenue adjustments for its flagship dry eye drug VEVYE, the company is seeing record prescriptions for VEVYE and strong unit demand for other products like IHEEZO and TRIESENCE. Harrow, Inc. specializes in ophthalmic pharmaceuticals, developing and marketing treatments for various eye conditions.
Harrow to Present at William Blair’s 46th Annual Growth Stock Conference
Harrow, Inc. (Nasdaq: HROW), a prominent provider of ophthalmic disease management solutions in North America, announced its participation in William Blair’s 46th Annual Growth Stock Conference. Management will deliver a presentation on Wednesday, June 3, 2026, at 8:40 AM CT in Chicago, IL. A live webcast and replay of the presentation will be available on the company’s website.
Harrow (HROW) Is Up 6.8% After Reaffirming 2026 Revenue Outlook Despite Wider Q1 Losses - What's Changed
Harrow (HROW) saw its stock rise 6.8% after it reaffirmed its full-year 2026 revenue guidance of $350 million to $365 million, despite reporting wider losses and lower revenue in Q1 2026 compared to the previous year. This reaffirmation signals management's confidence in its product portfolio, putting increased pressure on the company to perform strongly in the remaining quarters. The article emphasizes that while analysts had more optimistic revenue projections previously, the Q1 results serve as a reminder of potential risks associated with heavier spending and product concentration.
Harrow (HROW) Is Up 6.8% After Reaffirming 2026 Revenue Outlook Despite Wider Q1 Losses - What's Changed
Harrow, Inc. (HROW) saw its stock rise by 6.8% despite reporting wider Q1 2026 losses and a revenue decline compared to the previous year. The company reaffirmed its full-year 2026 revenue guidance of US$350 million to US$365 million and provided strong Q2 2026 guidance, indicating management's confidence in its product portfolio. This reaffirmation highlights the company's commitment to its growth-focused investment narrative, while analysts continue to assess the balance between ambitious revenue targets and execution risks.
Insider Buying: Adrienne Graves Acquires Shares of Harrow Inc (HROW)
Adrienne Graves, a Director at Harrow Inc, purchased 1,000 shares of the company on May 18, 2026, increasing her total ownership to 1,000 shares. Harrow Inc (HROW) is engaged in the development, production, and sale of innovative pharmaceutical products. The stock was trading at $31.07 on the day of the purchase, and its GF Value suggests it is modestly undervalued at $40.59.
Harrow, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:HROW)
Harrow, Inc. published its Q1 2026 earnings call presentation on May 19, 2026. The article features the slide deck released by Harrow, Inc. in conjunction with their earnings call, prepared by Seeking Alpha's transcripts team. It provides key details for investors and followers of HROW.
Harrow: Demand Keeps It Interesting, Valuation Keeps It A Hold
Harrow is currently rated as a Hold despite strong demand for its ophthalmic products, due to execution risks revealed in Q1 2026. The company missed revenue and adjusted EBITDA expectations, highlighting challenges in converting prescription growth into predictable financial results, particularly with products like VEVYE and IHEEZO. Achieving its 2026 guidance will require significant revenue acceleration and EBITDA recovery, but the market's current valuation already appears to factor in a successful turnaround.
Harrow, Inc. 2026 Q1 - Results - Earnings Call Presentation
This article provides the slide deck presented by Harrow, Inc. during their Q1 2026 earnings call on May 19, 2026. The slide deck contains crucial information discussed by the company regarding their financial performance and outlook. This publication offers investors and interested parties direct access to the materials used in the presentation.
Harrow director Adrienne Graves buys $31,070 in company stock By Investing.com
Adrienne L. Graves, a director at HARROW, INC. (NASDAQ: HROW), recently purchased 1,000 shares of the company's common stock for a total of $31,070. This acquisition comes as the stock trades near $30.90, down 37% year-to-date, with InvestingPro analysis suggesting the company may be undervalued. This insider purchase follows a recent financial report where Harrow Health Inc. missed Q1 2026 earnings and revenue expectations.
Insider Buying: Adrienne Graves Acquires Shares of Harrow Inc (HROW)
Adrienne Graves, a Director at Harrow Inc (HROW), recently purchased 1,000 shares of the company, increasing her total ownership to 1,000 shares. The transaction occurred on May 18, 2026, with shares trading at $31.07. According to GuruFocus's GF Value of $40.59, Harrow Inc is considered modestly undervalued with a price-to-GF-Value ratio of 0.77.
Harrow director Lauren Silvernail buys $31,000 in company stock
Harrow director Lauren P. Silvernail purchased 1,000 shares of HARROW, INC. common stock for $31,000 on May 18, 2026, increasing her direct holdings to 1,000 shares. This insider buying occurs as the stock is down 37% year-to-date and follows a recent Q1 2026 earnings report where Harrow Health Inc. missed revenue and EPS expectations.
